Orange Book drug · Generic (ANDA)

Levofloxacin In Dextrose 5% In Plastic Container

Levofloxacin

ANDA 090343 3 strengths Inforlife

Approved

Jul 07, 2011

Strengths

Listed patents

Applications

What does the FDA Orange Book show for Levofloxacin In Dextrose 5% In Plastic Container?

Levofloxacin In Dextrose 5% In Plastic Container contains Levofloxacin and appears in 8 FDA Orange Book applications. ANDA 090343 is the lead filing, with 3 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications: 8; lead ANDA 090343
Lead application holder: Inforlife Sa
Product presentations: 3
Marketing categories: Prescription
Reference roles: RS
TE codes: AP
Listed patents: 0
Exclusivity records: 0

Sourced from the official FDA Orange Book data file · snapshot refreshed Jul 02, 2026, 06:34 PM

FDA product-presentation matrix

Every product number in this exact application

Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
Product	Strength	Dosage form / route	Marketing status	TE code	Reference role
001	EQ 250MG/50ML (EQ 5MG/ML)	INJECTABLEINJECTION	Prescription	AP	RS
002	EQ 500MG/100ML (EQ 5MG/ML)	INJECTABLEINJECTION	Prescription	AP	RS
003	EQ 750MG/150ML (EQ 5MG/ML)	INJECTABLEINJECTION	Prescription	AP	RS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Inforlife Sa

The Orange Book identifies this organization as the applicant responsible for ANDA 090343.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not

FDA marketing status

3 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AP across rated presentations

An AP code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.

Patent & exclusivity record

No listed patents or exclusivity records

This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.

Same-ingredient landscape

35 other ANDAs and 5 other NDAs found

17 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

ANDA 090343 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Injectable · Injection

Levofloxacin

17 applications

Product rows: 44
Active applications: 7
Active with AB row: 0

Levaquin · NDA 020635 Levofloxacin · ANDA 205540 Levofloxacin · ANDA 205968 Levofloxacin · ANDA 078577 Levofloxacin · ANDA 091436 Levofloxacin · ANDA 202590

Why are clinical sections unavailable?

Exact application-label matching status

Exact source match queuedQueue ANDA-090343

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

3 approved presentations · ANDA 090343

TE APRS

Strength: EQ 250MG/50ML (EQ 5MG/ML)
Dosage form: INJECTABLE
Route: INJECTION
Marketing status: Prescription

Key dates

Approval, patents, exclusivity

Approval
FDA approval date of this drug product.
Jul 07, 2011
15 yr 3 mo ago
Today

Pharmaceutical detail

FDA product record

Active ingredient

LEVOFLOXACIN

Strength

EQ 250MG/50ML (EQ 5MG/ML)

Dosage form

INJECTABLE

Route

INJECTION

TE code

Application

ANDA 090343

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Reference standard (RS)

Yes

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Other FDA applications for Levofloxacin In Dextrose 5% In Plastic Container

7 additional filings · 7 generic

The FDA has approved 8 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Levofloxacin In Dextrose 5% In Plastic Container, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
Application	Applicant	Approved	Strengths	TE code	Status
ANDA 078579	Hospira	Sep 03, 2015	3	AP	Prescription
ANDA 091375	Hikma Farmaceutica	Sep 16, 2011	3	AP	Prescription
ANDA 091397	Baxter Hlthcare Corp	Aug 08, 2013	3	—	Discontinued
ANDA 200674	Fresenius Kabi USA	Jun 19, 2013	3	AP	Prescription
ANDA 206908	Gland	Dec 30, 2020	3	AP	Prescription
ANDA 206919	Eugia Pharma	Feb 10, 2016	3	—	Discontinued
ANDA 216164	Knack	Jan 29, 2024	3	—	Discontinued

Active-ingredient family

Brand + generics

Generic (ANDA) of Levofloxacin

View full Levofloxacin family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.